The research team, led by Marcus Vetter and Elena Diana Chiru of Cantonal Hospital Basel-Land and the University of Basel, together with collaborators at APIS Assay Technologies in Manchester, examined the APIS Breast Cancer Subtyping Kit, or BCSK, in 141 adults diagnosed with early luminal HER2-negative breast cancer between 2020 and 2022 at Cantonal Hospital Basel-Land and Basel University Hospital. Every patient in the cohort already had a valid Oncotype DX Recurrence Score on file and was planned to receive at least one line of adjuvant therapy, allowing the investigators to benchmark the newer assay against one of the most widely used genomic tests in breast oncology. In a subset of 59 patients, the team also performed the Prosigna PAM50 test, which yields an intrinsic molecular subtype and a risk of recurrence score.

The technical foundation of the APIS kit is reverse transcription quantitative polymerase chain reaction, a workhorse method of molecular pathology. The assay measures the expression of seven genes in formalin-fixed, paraffin-embedded tissue: ESR1, the gene encoding the estrogen receptor; PGR, encoding the progesterone receptor; ERBB2, encoding HER2; and MKI67, which encodes the proliferation marker Ki-67, alongside three additional proliferation genes, CCNA2, PCNA, and KIF23. From the relative expression of the four proliferation markers, a logistic model calculates a proliferation score between zero and one, with values below 0.5 classified as low proliferation and values above 0.5 as high proliferation. This quantitative, mRNA-level approach is designed to sidestep a well-known weakness of routine diagnostics: immunohistochemical measurement of Ki-67 is notoriously prone to preanalytical and analytical variability, as well as disagreement between observers, which can ripple into clinical decision-making.

The concordance results at the level of individual markers were striking. The BCSK showed essentially perfect agreement with immunohistochemistry for the estrogen receptor, at 99.29 percent, and for HER2, where all 141 samples were concordantly negative. Agreement for the progesterone receptor reached 86.52 percent. The proliferation marker told a more nuanced story. When Ki-67 staining from the original core needle biopsy was compared with the qPCR result from the resected specimen, positive percent agreement was only 43.55 percent, likely reflecting genuine tumor heterogeneity between a small biopsy and the larger resection. But when both the immunohistochemistry and the RNA test were performed on matched resected tissue, overall agreement rose to 71.19 percent, supporting the idea that much of the apparent discordance stems from comparing different tissue pieces rather than from flaws in the molecular assay itself.

Moving from single markers to molecular subtypes, the BCSK agreed with the Prosigna PAM50 classification in 71.2 percent of cases, an encouraging result for a test built on just seven genes. Perhaps more notable was the comparison with routine immunohistochemistry-based subtyping. The BCSK achieved an overall percent agreement of 71.2 percent with IHC-defined subtypes, whereas the PAM50 agreed with IHC in only 54.2 percent of cases. In other words, the inexpensive qPCR kit tracked conventional pathology assessments more closely than the established nanoscale gene-expression platform did. Three cases labeled luminal B by IHC were reclassified as basal-like by PAM50, and one was labeled HER2-enriched, underscoring how different platforms can meaningfully reshape a tumor’s molecular portrait.

The heart of the study lies in how the APIS proliferation score performs as a risk stratification tool when set against the two commercially validated recurrence scores. Treating all three as continuous variables, the researchers found a moderate positive correlation between the APIS score and the Prosigna risk of recurrence score, with a Spearman coefficient of 0.4787, and a somewhat weaker correlation with the Oncotype DX Recurrence Score, at 0.4006. Tellingly, the correlation between Prosigna and Oncotype DX themselves was weak in this cohort, at just 0.2255. That observation echoes earlier findings from the OPTIMA prelim trial, in which fewer than 40 percent of patients were classified alike by the two established assays, a reminder that these tools measure overlapping but distinct biological signals. Oncotype DX thresholds its proliferation component and blends it with an estrogen signaling module including PGR expression, whereas Prosigna and the APIS score lean more directly on proliferation, which transcriptomic studies suggest carries much of the prognostic information in breast cancer.

The risk distributions themselves were revealing. Within the 59-patient subset, Prosigna classified 23.7 percent of cases as low risk, 44.1 percent as intermediate, and 32.3 percent as high. Oncotype DX placed 67.8 percent in the low-risk category, 6.8 percent in the intermediate, and 25.4 percent in the high category. The APIS proliferation score, using its binary cutoff, labeled 39 percent of cases as low risk and a striking 61 percent as high risk, suggesting a more conservative stance toward stratification. During the study’s follow-up window, four patients experienced clinical relapse; two of them had been classified as high risk by both Oncotype DX and the APIS proliferation score, and one had a high Prosigna risk of recurrence score. The authors are careful to note that with so few events, no meaningful outcome analysis is possible, and the trial was not designed or powered for that purpose.

The clinical and economic arguments woven through the paper are as compelling as the analytical data. Established prognostic gene-expression assays cost between roughly 1,500 and 2,500 pounds, and reimbursement criteria exclude many patients who might still benefit from molecular risk assessment. The APIS kit, by contrast, is described as cost-neutral relative to routine immunohistochemistry, uses the same formalin-fixed paraffin-embedded blocks already collected at diagnosis, and can in principle be run and reported by local pathology laboratories rather than centralized reference facilities. Because results could be available from the initial core needle biopsy, the proliferation score might inform the very first multidisciplinary team discussion, flagging patients with very high or very low scores for whom additional costly testing may be unnecessary, while reserving full multigene assays for cases with intermediate scores near the cutoff.

The study’s limitations deserve equal billing with its promise. The cohort of 141 patients, and the subset of 59 tested with PAM50, are small and may not capture the heterogeneity of the broader breast cancer population. Follow-up was short and clinical events were rare, so the analysis speaks to analytical concordance rather than proven prognostic power. Most immunohistochemistry was performed on core needle biopsies with limited validation on matched resections, and the retrospective design meant that molecular results could not influence the treatment decisions actually made. There is also an industry dimension that readers should weigh: five co-authors are employed by APIS Assay Technologies, and the company funded the study and was involved in its design, analysis, and writing.

Even with those caveats, the study marks a meaningful proof of concept. It demonstrates that a compact, seven-gene qPCR assay can reproduce receptor status with near-perfect fidelity, approximate molecular subtyping, and generate a proliferation score that correlates with the drivers of two clinically validated recurrence tests, all at a cost structure that could democratize access to molecular profiling. If larger studies with longer follow-up confirm that the proliferation score reliably identifies patients who can safely forgo chemotherapy, this locally run, biopsy-based approach could reshape the diagnostic pathway for the roughly 65 percent of breast cancer patients whose tumors are hormone receptor-positive and HER2-negative. The message for patients and clinicians alike is one of cautious optimism: the tools for cheaper, faster, and more reproducible risk assessment are edging closer to the clinic, but the decisive validation trials are still to come.

Subject of Research: Evaluation of an RNA-based qPCR assay for molecular subtyping and proliferation-based recurrence risk prediction in early HR-positive, HER2-negative breast cancer.

Article Title: Evaluating an RNA-based test for proliferation assessment and recurrence prediction in early HR+/HER2− breast cancer

Article References: Evaluating an RNA-based test for proliferation assessment and recurrence prediction in early HR+/HER2− breast cancer. (n.d.). https://doi.org/10.3389/pore.2025.1612113

Image Credits: AI Generated

DOI: 10.3389/pore.2025.1612113

Keywords: breast cancer, RNA-based testing, molecular subtyping, proliferation score, Oncotype DX, Prosigna PAM50, Ki-67, recurrence risk, endocrine therapy, adjuvant chemotherapy, qPCR, biomarkers

Head and neck squamous cell carcinoma, abbreviated HNSCC, is one of the most common cancers worldwide, arising from the flat cells that line the mucosal surfaces of the larynx, pharynx, oral cavity and related structures. Because these tumors develop in a region that is continuously bathed in saliva and colonized by hundreds of microbial species, researchers have long suspected that the oral microbiome might play an active role in the disease. The concept has gained traction under the name of the oncobiome: the idea that microorganisms within the tumor microenvironment are not passive bystanders but may influence how tumors form, how they respond to therapy, and ultimately how patients fare. The new study provides some of the most concrete evidence yet that this influence extends to survival itself.

The research was designed as a prospective study, meaning that patients were enrolled and sampled according to a predefined protocol rather than retrospectively selected from archived material. The cohort included 86 patients with laryngeal carcinoma and 38 with pharyngeal carcinoma, alongside the 66 healthy controls. Saliva was collected with informed consent under ethical approvals from the Hospital Universitario Central de Asturias and the regional ethics committee of the Principality of Asturias. The team then applied 16S rRNA gene sequencing, a technique that reads a specific genetic marker found in all bacteria, allowing researchers to identify which genera and species are present in each sample and in what relative proportions, without needing to culture the organisms in the laboratory.

The first major finding was that cancer patients and healthy controls carried clearly distinct microbial community profiles. Just as striking was the discovery of pronounced site-specific dysbiosis, meaning that the pattern of microbial imbalance differed depending on where in the upper aerodigestive tract the tumor had arisen. Pharyngeal tumors and laryngeal tumors were associated with different salivary bacterial landscapes, a detail that matters because most previous studies have treated head and neck cancer as a single entity. The anatomical context of the tumor, in other words, appears to shape the ecology of the mouth around it, and any biomarker derived from saliva would need to respect that context to be clinically useful.

Treatment itself also left a microbial fingerprint. The researchers compared microbiome composition before and after therapy and found that chemoradiotherapy, the combination of chemotherapy and radiation used in many HNSCC patients, induced a marked remodeling of the oncobiome. The most notable post-treatment change was an enrichment of Lactobacillus, a genus of lactic acid bacteria that is often abundant in altered oral environments. Whether this shift is a consequence of tissue damage, changes in saliva production and pH, or a direct selective effect of the treatment on bacterial growth remains an open question, but it demonstrates that the salivary microbiome is a dynamic system that responds to clinical intervention rather than a fixed attribute of the patient.

The centerpiece of the study, however, is a ten-bacteria salivary signature associated with poorer survival outcomes. Using statistical models, the team identified a specific combination of bacterial taxa whose collective abundance in saliva was linked to worse disease-specific survival, worse overall survival, and worse disease-free survival, the three standard endpoints used in oncology. The strength of the association was remarkable. In multivariable Cox regression analysis, which adjusts for established clinicopathological variables such as tumor stage and site, the ten-bacterial signature remained independently associated with poor prognosis, with a hazard ratio of 6.215 for disease-specific survival, 5.417 for overall survival, and 6.842 for disease-free survival, all with p values below 0.001. Hazard ratios of this magnitude indicate that patients carrying the adverse signature faced a roughly five- to seven-fold higher risk of death or recurrence compared with patients whose salivary microbiome lacked it.

Beyond the unified signature, the study uncovered tumor site-specific prognostic taxa, bacteria whose association with survival depended on where the tumor was located. In pharyngeal carcinomas, the presence of putative species belonging to the genera Prevotella, Porphyromonas and Fusobacterium correlated significantly with improved disease-specific, overall and disease-free survival. This is a counterintuitive result, because Fusobacterium in particular has been implicated in promoting colorectal tumors, yet here its presence in the saliva of pharyngeal cancer patients was associated with a favorable outcome. In laryngeal carcinomas, a different set of organisms told a different story: putative Stomatobaculum longum and Dialister were associated with favorable survival outcomes. The authors interpret these findings as support for the concept of an anatomically contextualized oncobiome, in which the prognostic meaning of a given bacterium cannot be separated from the anatomical site of the tumor it accompanies.

Technically, the study relied on ANCOM-BC, a modern differential abundance method that corrects for the compositional nature of sequencing data, to compare microbial communities between groups. Prognostic associations were then tested with univariable and multivariable Cox proportional hazards models, the standard framework for survival analysis in medicine, supplemented by Kaplan-Meier style survival analyses. The word putative in the species-level assignments reflects a limitation of 16S rRNA sequencing: because the method reads only a marker gene rather than whole genomes, it can often identify a bacterium only to the genus level, with species-level calls made by inference. Higher-resolution approaches such as shotgun metagenomic sequencing would be needed to confirm the exact species and strains involved, and the authors are explicit that validation in independent cohorts is required before any clinical implementation.

Even with those caveats, the implications are considerable. Current prognostic assessment in HNSCC rests largely on tumor staging, grading, anatomical site and a handful of molecular markers, all of which are typically obtained through invasive biopsies and imaging. A salivary microbiome signature offers something different: a non-invasive, dynamic biomarker that can in principle be sampled repeatedly over time, before treatment, during follow-up, and at the first suspicion of recurrence. Because saliva collection is cheap, painless and acceptable to patients, a validated microbial risk score could be integrated into routine surveillance, helping clinicians decide which patients need intensified follow-up imaging or adjuvant therapy and which can be monitored less aggressively. It could also, in the longer term, open the door to microbiome-targeted interventions aimed at shifting the oral ecology toward a more favorable state.

The study was conducted by researchers from the Instituto de Investigación Sanitaria del Principado de Asturias in Oviedo, the University of Oviedo, the Spanish Biomedical Research Network in Cancer, the Dairy Research Institute of Asturias, the FISABIO Foundation in Valencia, and Dartmouth’s Geisel School of Medicine, with funding from the Instituto de Salud Carlos III and co-financing from the European Union and regional institutions. The work was published open access on 9 October 2026 in Microbiome under DOI 10.1186/s40168-026-02548-w. For now, the ten-bacteria signature remains a research finding rather than a bedside test, and the authors caution that larger, independent and higher-resolution studies must confirm the result. But the message is clear: the bacteria in a patient’s saliva are not just spectators to head and neck cancer. They form a readable, quantifiable signature of the disease’s trajectory, and learning to read it may reshape how survival risk is assessed in one of the world’s most challenging cancers.

Subject of Research: Salivary microbiome signatures as prognostic biomarkers for survival and recurrence in head and neck squamous cell carcinoma

Article Title: Salivary prognostic bacterial signatures associated with survival outcomes and recurrence risk in head and neck squamous cell carcinoma

Article References: Granda-Díaz, R., Molinero, N., Sánchez-Canteli, M., Álvarez-Teijeiro, S., Mira, A., Allonca, E., Quesada, V., Margolles, A., Martínez-Camblor, P., Martín-Guillermo, E., Delgado, S., Rodrigo, J. P., & García-Pedrero, J. M. (2026). Salivary prognostic bacterial signatures associated with survival outcomes and recurrence risk in head and neck squamous cell carcinoma. Microbiome. https://doi.org/10.1186/s40168-026-02548-w

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02548-w

Keywords: salivary microbiome, head and neck squamous cell carcinoma, oncobiome, 16S rRNA sequencing, prognostic biomarkers, dysbiosis, Lactobacillus, Fusobacterium, chemoradiotherapy, survival analysis, recurrence risk, Microbiome journal

The question of whether young age is an independent prognostic factor in breast cancer has divided researchers for decades. Breast cancer remains the fourth leading cause of cancer-related death worldwide, and young age at diagnosis has repeatedly been linked to higher recurrence rates and shorter disease-free survival. Skeptics have argued that the apparent disadvantage simply reflects confounding: young patients tend to present with more aggressive tumor biology, including high-grade disease, lymphovascular invasion, elevated proliferation, and an enrichment of hormone receptor-negative, HER2-positive, and basal-like tumors. They are also more frequently diagnosed at advanced stages. Yet several large analyses have found that young age persists as a risk factor even after adjustment for stage and receptor status, and patients under 35 show increased risks of recurrence and distant metastasis that pathological features alone cannot explain.

To dissect this puzzle, the study drew on the TCGA PanCancer Atlas Breast Invasive Carcinoma cohort accessed through cBioPortal. After a careful filtering process that excluded stage IV disease, unknown stages, and tumors with Normal-like or missing PAM50 classifications, the final analytical cohort comprised 821 patients with invasive ductal or invasive lobular carcinoma: 142 aged 45 years or younger and 679 older than 45. The cutoff of 45 years was chosen to align with previous genomic studies, and sensitivity analyses using thresholds of 35, 40, and 50 years were performed to guard against the arbitrariness of any single definition of “young.”

The clinicopathological comparison revealed that young patients were significantly more likely to have invasive ductal carcinoma, at 94.4 percent versus 79.4 percent in older patients, and more likely to have lymph node involvement, with only 38 percent showing node-negative disease compared with 51.2 percent of older patients. Notably, however, estrogen receptor, progesterone receptor, HER2 status, intrinsic subtype, tumor size, and overall stage distribution did not differ significantly between the groups. Survival analyses then showed that young patients had significantly worse disease-free survival, with a log-rank p-value of 0.001, while overall survival and disease-specific survival did not differ significantly. The absolute burden of recurrence was striking: five-year disease-free survival event rates were 23.1 percent in young patients versus 10.8 percent in older patients, widening to 35.7 percent versus 13.8 percent at ten years. Restricted mean survival time analysis quantified a loss of 2.9 months within five years and 13.9 months within ten years for young patients, indicating that the prognostic gap widened over time.

The core of the study lay in constructing the molecular signature. Differential expression analysis between age groups identified 614 age-associated genes at a false discovery rate below 0.1, while univariable Cox regression flagged 529 genes linked to disease-free survival at a p-value below 0.01. Intersecting these sets yielded 11 candidates, which were then subjected to LASSO-Cox regression with 10-fold cross-validation, followed by stepwise multivariable selection based on the Akaike information criterion. The result was a parsimonious four-gene model comprising C4orf14, also known as NOA1, LINC01124, ZNF704, and AGFG2. Each patient’s Sig4 score was calculated as a weighted linear combination of the log2-transformed expression values of these genes, with fixed regression coefficients derived from the TCGA cohort.

The statistical performance of Sig4 was the study’s most provocative finding. In univariable analysis, young age carried a hazard ratio of 2.44 for poor disease-free survival, and this association remained significant after adjustment for stage and intrinsic subtype. But when the continuous Sig4 score was added to the fully adjusted model, Sig4 itself emerged as a strong independent predictor, with a hazard ratio of 2.18 per one-standard-deviation increase, while the coefficient for young age attenuated to a statistically non-significant 1.43. The author is careful to note that this attenuation indicates overlapping prognostic information between age and the signature, but does not prove that Sig4 mediates or causally explains the age effect. Within the young subgroup alone, Sig4 remained independently associated with disease-free survival, a result reinforced by bootstrap resampling with 1000 iterations, and descriptive Kaplan-Meier curves showed significantly poorer survival among young patients with high Sig4 scores.

Biological context came from gene set enrichment analysis. Tumors with high Sig4 scores were enriched for proliferation- and cell cycle-related pathways, including MYC targets, E2F targets, the G2-M checkpoint, and mitotic spindle assembly, along with DNA repair, mTORC1 signaling, glycolysis, oxidative phosphorylation, and the unfolded protein response. In contrast, Sig4-low tumors showed relative enrichment of early and late estrogen response pathways. Single-sample enrichment analysis confirmed these differences at the individual tumor level. The four component genes themselves span diverse functions: NOA1 is a mitochondrial GTPase involved in mitoribosome biogenesis and respiration; LINC01124 is a long noncoding RNA implicated in proliferation and invasion; ZNF704 is a zinc finger repressor linked to circadian disruption and metastasis in breast cancer; and AGFG2 participates in vesicular trafficking, potentially reflecting tumor-microenvironment interactions.

External validation in the independent METABRIC cohort of 1134 matched cases provided partial support. Using the fixed TCGA-derived coefficients, the Sig4 score was significantly associated with worse relapse-free survival both as a continuous variable and when dichotomized at the cohort median, and Sig4-high status remained significant in multivariable models, in stratified Cox analyses, and in models incorporating a time-varying coefficient for young age. However, the validation was not uniformly successful: when the analysis was restricted to young METABRIC patients aged 45 or younger, the Sig4 score showed no significant association with relapse-free survival. The author attributes this to possible differences in cohort composition, treatment background, expression platform, endpoint definitions, and statistical precision, and concludes that the signature’s utility specifically for young-onset disease remains unproven.

The study is candid about its limitations. It is a retrospective analysis of public datasets with incomplete treatment and hereditary predisposition information, meaning that chemotherapy, endocrine therapy, HER2-targeted treatment, and germline BRCA status could all have influenced the observed associations. The limited number of disease-free survival events relative to the number of genes screened raises the specter of overfitting, despite the penalized regression approach, and the bulk RNA sequencing data cannot separate tumor-intrinsic programs from microenvironmental contributions. The author therefore positions Sig4 as an exploratory candidate signature rather than a clinically applicable biomarker, emphasizing that translation into practice would require analytical standardization, prospective validation, and evidence that the score improves decisions beyond existing clinicopathological and molecular tools. Even so, the work offers a compelling demonstration that the transcriptomic landscape of young-onset breast cancer carries prognostic weight, and it points toward a future in which age-associated molecular signatures could help identify which young patients truly need intensified surveillance and therapy.

Subject of Research: An age-associated four-gene prognostic signature for recurrence risk in breast cancer

Article Title: Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer

Article References: Uchida, S. (2026). Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer. Cancer Reports, 9(9), Article e70670. https://doi.org/10.1002/cnr2.70670

Image Credits: AI Generated

DOI: 10.1002/cnr2.70670

Keywords: breast cancer, prognostic signature, young-onset breast cancer, gene expression, TCGA, METABRIC, disease-free survival, LASSO-Cox regression, molecular biomarker, recurrence risk, transcriptomics, Cancer Reports